Third Quarter Revenues of $394.2 Million GAAP Net Income of $82.8 Million and Diluted GAAP Earnings per Share of $0.49 Company Raises 2025 Financial Expectations DUBLIN , Oct. 28, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2025. "Alkermes delivered another successful quarter, achieving strong revenue growth and robust profitability, fueled by focused execution... Read More

Augments Revenue Growth Profile and Diversifies Alkermes' Commercial Portfolio with New High Growth Product, LUMRYZ™(Sodium Oxybate) Accelerates Alkermes' Commercial Entry into Sleep Medicine Market and Provides Strong Foundation for Potential Launch of Alixorexton Expected to be Immediately Accretive and Enhance Profitability Upon Closing Positions the Combined Organization to Accelerate Innovation and Expand its Leadership... Read More

DUBLIN , Oct. 20, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 12:00 p.m. GMT ) on Tuesday, Oct. 28, 2025 to discuss the company's third quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com . The conference call may be accessed by dialing +1 877 407 2988... Read More

DUBLIN , Sept. 12, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) is pleased to announce the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept. 15, 2025 . Mr. Reed will report to Richard Pops, Chief Executive Officer of Alkermes, and will join the company's management committee. "I'm delighted to be joining Alkermes and look forward to working with Richard and the team to build on... Read More

Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project Areas of Interest Expanded to Include Sleep and Circadian Disturbances Associated With Bipolar I Disorder and/or Schizophrenia Application Period to Run From Sept. 15, 2025 Through Dec. 15, 2025 DUBLIN , Sept. 11, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes... Read More

First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Impact on Wakefulness, Cognition and Fatigue with Once-Daily Dosing Across a Range of Doses Alixorexton Was Generally Well Tolerated at All Doses Tested Company to Host Investor Webcast on Monday, Sept. 8 at 8:00 a.m. ET DUBLIN , Sept. 7, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced detailed positive results... Read More

– Results From Vibrance-1 to Be Shared in Three Oral Presentations, Including Primary and Secondary Efficacy and Safety Measures, and Exploratory Patient-Reported Outcomes Related to Disease Severity, Fatigue and Cognition – – Company to Host Investor Webcast on Monday, Sept. 8 at 8:00 a.m. ET – DUBLIN , Aug. 25, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present detailed results from its... Read More

Second Quarter Revenues of $390.7 Million GAAP Net Income of $87.1 Million and Diluted GAAP Earnings per Share of $0.52 Company Reiterates 2025 Financial Expectations Alkermes to Present Detailed Vibrance-1 Results at Upcoming World Sleep Congress DUBLIN , July 29, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2025. "Our second quarter results reflect strong... Read More

Alixorexton Demonstrated Clinically Meaningful and Statistically Significant Improvements in Wakefulness at All Doses Tested Compared to Placebo in Patients With Narcolepsy Type 1 Alixorexton Demonstrated Robust and Consistent Improvements in Patient-Reported Outcomes Related to Disease Severity, Fatigue and Cognition at All Doses Tested Alixorexton Was Generally Well Tolerated at All Doses Tested Detailed Results to Be... Read More

DUBLIN , July 15, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Tuesday, July 29, 2025 to discuss the company's second quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com . The conference call may be accessed by dialing +1 877 407 2988... Read More

DUBLIN , June 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat presentation at the Goldman Sachs 46 th Annual Global Healthcare Conference on Monday, June 9, 2025 at 10:00 a.m. EDT ( 3:00 p.m. BST ). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc is a global... Read More

Multiple Subgroup Analyses Presented From Long-Term Safety Study of LYBALVI ® (olanzapine and samidorphan), Including Data on Lipid and Glycemic Profiles DUBLIN , June 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of accepted research at key scientific conferences this spring, including presentations largely related to its psychiatry products LYBALVI ® (olanzapine and samidorphan) and... Read More

Company to Present Eight Posters and Two Oral Presentations, Including New Analyses From ALKS 2680 Phase 1 Study New Research Evaluating the Clinical, Economic and Humanistic Burden of Narcolepsy and Findings From In-Depth Qualitative Patient Interviews on the Burden of Idiopathic Hypersomnia Will Also Be Presented DUBLIN , May 29, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present new research... Read More

First Quarter Revenues of $306.5 Million GAAP Net Income of $22.5 Million and Diluted GAAP Earnings per Share of $0.13 Company Reiterates 2025 Financial Expectations DUBLIN , May 1, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2025. "Our first quarter financial performance provides a solid foundation to deliver on our financial guidance for the year. We are in a... Read More

Survey Respondents Reported That AUD Diagnosis and Decision to Seek Treatment Were Driven by Negative Consequences of Drinking Respondents Cited the Influence of Their Healthcare Providers and the Positive Impact of Treatment on Their Lives DUBLIN , April 30, 2025 /PRNewswire/ -- A new online survey conducted by The Harris Poll on behalf of Alkermes, Inc., a subsidiary of Alkermes plc (Nasdaq: ALKS), sought to understand... Read More

DUBLIN , April 17, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Thursday, May 1, 2025 to discuss the company's first quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com . The conference call may be accessed by dialing +1 877 407 2988... Read More

DUBLIN , April 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a webcast panel discussion " Development of Orexin Receptor Agonist in Sleep-Wake Disorders " at the upcoming 24 th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 11:45 a.m. EDT ( 4:45 p.m. BST ). The live webcast may be accessed under the Investors tab on www.alkermes.com and... Read More

DUBLIN , April 1, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to placebo in adults with idiopathic hypersomnia (IH). ALKS 2680 is the company's novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy type 1, narcolepsy... Read More

Survey Respondents Reported That Medication Adherence is a Top Concern for Healthcare Providers When Selecting Treatments and Frequent Medication Switches Can Have Significant Impacts on Patients' Experiences and Quality of Life 98% of Respondents Agreed* That Quality of Life for a Patient is Just as Important as Symptom Management When Thinking About Treatment Effect DUBLIN , March 27, 2025 /PRNewswire/ -- People living... Read More

DUBLIN , Feb. 26, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in webcast fireside chats at two upcoming investor conferences. TD Cowen 45 th Annual Health Care Conference Date/Time: Wednesday, March 5, 2025 at 9:50 a.m. ET ( 2:50 p.m. GMT ) Leerink Partners Global Healthcare Conference 2025 Date/Time: Wednesday, March 12, 2025 at 11:20 a.m. ET ( 3:20 p.m. GMT ) The live... Read More

Total Revenues of $1.56 Billion in 2024; Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year GAAP Net Income from Continuing Operations of $372 Million and Diluted GAAP Earnings per Share from Continuing Operations of $2.20 for 2024 ALKS 2680 Phase 2 Studies in Narcolepsy Type 1 and Type 2 Ongoing With Data Expected in H2 2025 DUBLIN , Feb. 12 , 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today... Read More

DUBLIN , Feb. 5, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. GMT ) on Wednesday, Feb. 12, 2025 to discuss the company's fourth quarter and year-end 2024 financial results. Management will also discuss financial expectations for 2025 and provide an update on the company. The webcast player and accompanying slides may be accessed on the... Read More

DUBLIN , Jan. 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops , will provide a corporate overview and update at the 43 rd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Wednesday, Jan. 15, 2025 at 11:15 a.m. PST ( 2:15 p.m. EST / 7:15 p.m. GMT ), followed by a question and answer session. The live webcast may be accessed under... Read More

DUBLIN , Nov. 25, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. 7 th Annual Evercore ISI HealthCONx Conference Date/Time: Tuesday, Dec . 3, 2024 at 10:25 a.m. ET ( 3:25 p.m. GMT ) Piper Sandler 36 th Annual Healthcare Conference Date/Time: Wednesday, Dec . 4, 2024 at 4:00 p.m. ET ( 9:00 p.m. GMT ) The live webcasts may be accessed under... Read More

DUBLIN , Nov. 11, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate at two upcoming investor conferences. Stifel Healthcare Conference Date/Time: Monday, Nov. 18, 2024 at 8:35 a.m. ET ( 1:35 p.m. GMT ) Jefferies London Healthcare Conference Date/Time: Tuesday, Nov. 19, 2024 at 8:00 a.m. ET ( 1:00 p.m. GMT ) The live webcasts may be accessed under the Investors tab on... Read More

12 Poster Presentations Showcase Research in Schizophrenia, Bipolar I Disorder and Narcolepsy Results Presented From Real-World Retrospective Study of Healthcare Resource Utilization and Treatment Patterns in Patients With Schizophrenia or Bipolar I Disorder Following Initiation of LYBALVI ® (olanzapine and samidorphan) DUBLIN , Nov. 7, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of... Read More

Third Quarter Revenues of $378.1 Million Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year GAAP Net Income from Continuing Operations of $92.8 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.56 Company Reiterates 2024 Financial Expectations DUBLIN , Oct. 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2024.... Read More

DUBLIN , Oct. 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Thursday, Oct. 24, 2024 to discuss the company's third quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com . The conference call may be accessed by dialing +1 877 407 2988... Read More

DUBLIN , Sept. 25, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that it will host an investor event for financial analysts and institutional investors on Wednesday, Oct. 9, 2024 starting at 10:00 a.m. EDT in Waltham, Mass. Members of Alkermes' Research & Development team will review the company's orexin portfolio and development strategy. The event will also feature a clinician and thought leader panel... Read More

Data From Narcolepsy Type 2 Cohort of ALKS 2680 Phase 1b Study to be Presented in Oral Presentation Data From Idiopathic Hypersomnia Cohort of ALKS 2680 Phase 1b Study Accepted for Poster Presentation DUBLIN , Sept. 23, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical data from its phase 1b study of ALKS 2680 in patients with narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) at... Read More

DUBLIN , Sept. 19, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat presentation at the TD Cowen 4 th Annual Novel Mechanisms in Neuropsychiatry Conference on Thursday, Sept. 26, 2024 at 9:20 a.m. EDT ( 2:20 p.m. BST ). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes... Read More

Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project Application Period to Run From Sept. 20, 2024 Through Nov. 30 , 2024 DUBLIN , Sept. 13, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards ® program on Friday, Sept. 20, 2024 . Now in its seventh year, this competitive grant program is... Read More

DUBLIN , Aug. 28 , 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat presentation at the Morgan Stanley 22 nd Annual Global Healthcare Conference on Wednesday, Sept. 4, 2024 at 2:35 p.m. EDT ( 7:35 p.m. BST ). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc is a... Read More

DUBLIN , Aug. 22, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-2 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared to placebo in adults with narcolepsy type 2 (NT2). ALKS 2680 is the company's novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy, a chronic,... Read More

Second Quarter Revenues of $399.1 Million Net Sales of Proprietary Products Increased Approximately 16% Year-Over-Year GAAP Net Income from Continuing Operations of $94.7 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.55 Company Reiterates 2024 Financial Expectations DUBLIN , July 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of... Read More

DUBLIN , July 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, July 24, 2024 to discuss the company's second quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com . The conference call may be accessed by dialing +1 877 407... Read More

Orexin 2 Receptor Agonist ALKS 2680 Demonstrated Clinically Meaningful and Statistically Significant Improvements from Baseline in Mean Sleep Latency Compared to Placebo at All Doses Tested ALKS 2680 Was Generally Well Tolerated at All Doses Tested Vibrance-1 Phase 2 Study of ALKS 2680 in Patients With Narcolepsy Type 1 Is Ongoing DUBLIN , June 3, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced new data from... Read More

DUBLIN , May 29, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor conferences. Jefferies Healthcare Conference Date/Time: Thursday, June 6, 2024 at 1:30 p.m. EDT ( 6:30 p.m. BST ) Goldman Sachs 45 th Annual Global Healthcare Conference Date/Time: Tuesday, June 11, 2024 at 10:40 a.m. EDT ( 3:40 p.m. BST ) The live webcasts... Read More

Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibrance-1 Phase 2 Study Design Accepted for Poster Presentations Findings From In-Depth Qualitative Patient Interviews on the Burden of Narcolepsy Will Also Be Presented DUBLIN , May 28, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present three posters related to ALKS 2680 at... Read More

̶Results from Long-Term Safety Study and Data from Healthcare Resource Utilization Research Offer Insights into Treatment Experiences for People Living with Schizophrenia or Bipolar I Disorder DUBLIN , May 14, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise products—LYBALVI ® (olanzapine and samidorphan) and ARISTADA ® (aripiprazole... Read More

DUBLIN , May 2, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk. In connection with the closing of the transaction, Alkermes will receive a one-time cash payment for the facility and certain related assets of approximately $91 million . "With the completion of the sale of the development and... Read More

First Quarter Revenues of $350.4 Million GAAP Net Income from Continuing Operations of $38.9 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.23 Company Reiterates 2024 Financial Expectations DUBLIN , May 1, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2024. "The first quarter of 2024 marks our first full quarter as a profitable,... Read More

DUBLIN , April 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared to placebo in patients with narcolepsy type 1 (NT1). ALKS 2680 is the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy, a chronic, neurological... Read More

DUBLIN , April 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, May 1, 2024 to discuss the company's first quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com . The conference call may be accessed by dialing +1 877 407 2988... Read More

Orexin 2 Receptor Agonist ALKS 2680 Demonstrated Clinically Meaningful and Statistically Significant Improvements from Baseline in Mean Sleep Latency Compared to Placebo at All Doses Tested in Both Narcolepsy Type 2 and Idiopathic Hypersomnia ALKS 2680 Was Generally Well Tolerated at All Doses Tested Dose-Dependent Effects and Pharmacodynamic Profile Support Advancement Into Planned Phase 2 Study DUBLIN , April 9, 2024... Read More

DUBLIN , April 8, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the oral presentation of clinical data at the 2024 Congress of the Schizophrenia International Research Society (SIRS), which took place April 3-7, 2024 in Florence, Italy . Analyses were presented from a phase 3, open-label extension study assessing the long-term safety, tolerability and durability of treatment effect of LYBALVI ® (olanzapine... Read More

DUBLIN , March 7, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors (the Board). Ms. Lurker is a seasoned healthcare executive and experienced board member who brings decades of pharmaceutical and biotechnology industry leadership experience and strong commercial expertise, including a track record of successful... Read More

Total Revenues of $1.66 Billion in 2023; Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year GAAP Net Income of $356 Million and Diluted GAAP Earnings per Share of $2.10 for 2023 Company Expects to Generate 30% EBITDA Margin in 2024 DUBLIN , Feb. 15, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2023 and provided financial... Read More

DUBLIN , Feb. 8, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. GMT ) on Thursday, Feb. 15, 2024 to discuss the company's fourth quarter and year-end 2023 financial results. Management will also discuss financial expectations for 2024 and provide an update on the company. The webcast player and accompanying slides may be accessed on the... Read More

DUBLIN , Jan. 3, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops , will provide a corporate overview and update at the 42 nd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Wednesday, Jan. 10, 2024 at 11:15 a.m. PST ( 2:15 p.m. EST / 7:15 p.m. GMT ), followed by a question and answer session. The live webcast may be accessed under... Read More

Results Demonstrated that LYBALVI was Generally Well Tolerated With Stability of Body Weight and Metabolic Profile, and Durable Symptom Control, for Up to Four Years of Treatment DUBLIN , Jan. 3, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced topline results from a phase 3, open-label extension study assessing the long-term safety, tolerability and durability of treatment effect of LYBALVI ® (olanzapine and... Read More

DUBLIN , Dec. 14, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has entered into a definitive agreement to sell its development and manufacturing facility in Athlone, Ireland to Novo Nordisk, a leading global healthcare company. Under the terms of the agreement, upon the closing of the transaction, Alkermes will be entitled to a one-time cash payment of $92.5 million for the facility and related... Read More

DUBLIN , Nov. 21, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor conferences. Piper Sandler 35 th Annual Healthcare Conference Date/Time: Tuesday, Nov. 28, 2023 at 11:00 a.m. ET ( 4:00 p.m. GMT ) 6th Annual Evercore ISI HealthCONx Conference Date/Time: Wednesday, Nov. 29, 2023 at 10:00 a.m. ET ( 3:00 p.m. GMT ) The live... Read More

Alkermes Emerges as Pure-Play, Profitable Neuroscience Company Alkermes Provides Updated Financial Expectations for 2023 DUBLIN , Nov. 15, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has completed the separation of its oncology business into Mural Oncology plc (Mural Oncology), a new, independent, publicly traded company. Alkermes is now a pure-play, profitable neuroscience company that will... Read More

DUBLIN , Nov. 7, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, Nov. 14, 2023 at 12:00 p.m. ET ( 5:00 p.m. GMT ). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc is a fully-integrated, global... Read More

DUBLIN , Oct. 31 , 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the Registration Statement on Form 10, as amended (Form 10), filed by Mural Oncology plc (Mural Oncology) was declared effective by the U.S. Securities and Exchange Commission (SEC). This Form 10 describes Alkermes' planned separation of its oncology business into Mural Oncology, which, upon completion of the separation, will be a new,... Read More

Third Quarter Revenues of $380.9 Million; Net Sales of Proprietary Products Increased Approximately 16% Year-Over-Year GAAP Net Income of $47.8 Million and Non-GAAP Net Income of $109.5 Million Company Reiterates Financial Expectations for Full-Year 2023 Separation of Oncology Business Expected to be Completed in November 2023 DUBLIN , Oct. 25, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results... Read More

Initial ALKS 2680 Data Demonstrated Dose-Dependent, Significantly Improved Sleep Latency Compared to Placebo in Narcolepsy Type 1 ALKS 2680 Was Generally Well Tolerated at All Doses Tested Pharmacokinetic Profile of ALKS 2680 Supports Once-Daily Dosing and Mimics the Natural Sleep/Wake Cycle Consistent, Dose-Dependent Effects Enable Dose Selection for Evaluation in Planned Phase 2 Study DUBLIN , Oct. 23, 2023 /PRNewswire/ --... Read More

DUBLIN , Oct. 18, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, Oct. 25, 2023 to discuss the company's third quarter financial results as well as initial clinical data related to ALKS 2680, the company's novel, investigational orexin 2 receptor agonist in development for the treatment of narcolepsy, that will be presented... Read More

Event to be Webcast on Tuesday, October 17 at 11:00 a.m. ET DUBLIN , Oct. 10 , 2023 /PRNewswire/ -- Mural Oncology plc , the publicly-traded oncology company that Alkermes plc (Nasdaq: ALKS) plans to establish in the fourth quarter of 2023 (Mural Oncology), will hold an investor webcast during which members of Mural Oncology's designated management team will provide an overview of the company, its pipeline and strategy. The... Read More

Oral Presentation to Include Initial Clinical Proof-of-Concept Data in Patients With Narcolepsy Type 1 for ALKS 2680, the Company's Investigational Orexin 2 Receptor Agonist DUBLIN , Oct. 10, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present new data related to ALKS 2680, the company's novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy, at... Read More

Poster Presentations Highlight Company's Broad Research Commitment to Serious Mental Illness, Addiction and Narcolepsy DUBLIN , Sept. 11, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of multiple posters highlighting real-world and clinical data at the 36th Annual Psych Congress (Psych Congress), which took place Sept. 6-10, 2023 in Nashville . This research reflects the company's... Read More

Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project Application Period to Run From Sept. 15, 2023 Through Nov. 30, 2023 DUBLIN , Sept. 7, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards ® program on Friday, Sept. 15, 2023 . Now in its sixth year, this competitive grant program is designed... Read More

DUBLIN , Sept. 5, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor conferences. Morgan Stanley 21 st Annual Global Healthcare Conference Date/Time: Monday, September 11, 2023 at 11:20 a.m. EDT ( 4:20 p.m. BST ) Cantor Fitzgerald Global Healthcare Conference Date/Time: Wednesday, September 27, 2023 at 11:30 a.m. EDT ( 4:30... Read More

Competitive Grants Program Awards Funding to 11 Innovative Programs Focused on People Living with Addiction, Serious Mental Illness or Cancer DUBLIN , Aug. 31, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the recipients of the 2023 Alkermes Inspiration Grants ® program. Grants were awarded to 11 nonprofit organizations working to address the needs of people living with addiction, serious mental illness or... Read More

Company Grants Teva a License to Market Generic VIVITROL Beginning in January 2027 DUBLIN , Aug. 30, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that the company entered into a settlement agreement with Teva Pharmaceuticals USA , Inc. ("Teva") to resolve the ongoing patent litigation between the parties in the U.S. District Court for the District of New Jersey related to VIVITROL ® (naltrexone for... Read More

Second Quarter Revenues of $617.4 Million Reflect Strong Performance of Proprietary Product Portfolio and Reinstatement of Long-Acting INVEGA ® Product Royalties Net Sales of Proprietary Products Increased Approximately 21% Year-Over-Year Prevailed in Janssen Arbitration; Recorded $248.4 Million in Back Royalties and Interest GAAP Net Income of $237.1 Million and Non-GAAP Net Income of $94.3 Million Financial Expectations... Read More

DUBLIN , July 19, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, July 26, 2023 to discuss the company's second quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com . The conference call may be accessed by dialing +1 877 407... Read More

No Sarissa Nominees Elected by Shareholders DUBLIN , June 29, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) (the Company) today announced that, at the Company's 2023 Annual General Meeting of Shareholders (the Annual Meeting), shareholders voted to re-elect all seven of Alkermes' director nominees – Emily Peterson Alva , Shane M. Cooke , Richard B. Gaynor , M.D., Cato T. Laurencin , M.D., Ph.D., Brian P. McKeon , Richard... Read More

Recommend Shareholders Vote "For" Alkermes' Seven Director Nominees On Company's White Proxy Card DUBLIN , June 26, 2023 /PRNewswire/ -- Today, seven of the recently-appointed independent directors of the Board of Directors (the Board) of Alkermes plc (Nasdaq: ALKS) (the Company) issued an open letter to the Company's shareholders in connection with the Company's upcoming 2023 Annual General Meeting of Shareholders, which is... Read More

Supports Alkermes' Existing Board and Notes Strong Positive Momentum Shares Board's Belief that Sarissa's Nominees Would Not Be Additive to the Board Notes Alkermes Board is "sufficiently independent, qualified and capable to oversee the Company" Reveals Material Underperformance at Majority of Companies During Sarissa Nominee Sarah Schlesinger's Board Tenure DUBLIN , June 21, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS)... Read More

Recognizes Alkermes' Value Enhancement Plan, Board Refreshment and Business Momentum Recommends Voting 'FOR' Shane Cooke and Richard Pops and All Unopposed Alkermes Nominees ISS' Flawed Profitability Analysis Disregards 2022 Janssen Royalties Alkermes Board Believes Alex Denner's Serial Nominee Sarah Schlesinger, M.D. is Not Independent of Sarissa DUBLIN , June 20, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) (the... Read More

Sarissa does not understand why the Alkermes independent directors refuse to add Sarissa representatives to the board Sarissa believes the addition of its representatives to the Alkermes board can unlock shareholder value and allow Alkermes to achieve its true potential GREENWICH, Conn. / Jun 13, 2023 / Business Wire / Sarissa Capital today released the following letter to shareholders of Alkermes plc (NASDAQ: ALKS): June... Read More

Sarissa's Proposed Candidates Would Not Bring New Skills to the Board Recommends Shareholders Vote "FOR" Alkermes' Director Nominees on Company's WHITE Proxy Card DUBLIN , June 13, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) (the Company) today issued a letter to its shareholders in connection with the Company's upcoming 2023 Annual General Meeting of Shareholders (the Annual Meeting), which is scheduled to be held on... Read More

Strategic, Operational and Governance Enhancements Have Driven Strong Stock Price Performance and TSR Outperformance in Comparison to Peers Reiterates Board's Belief that Sarissa Nominees Would Offer No Additive Skills to the Board Recommends Shareholders Vote "FOR" Alkermes' Board Nominees on Company's WHITE Proxy Card DUBLIN , June 8, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) (the Company) today announced that it... Read More

Company Raises 2023 Revenue and GAAP Net Income Expectations by Approximately $425 Million Conference Call Scheduled for Today at 8:00 a.m. ET DUBLIN , June 6, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that on May 31, 2023 it received a final award (the Final Award) from the arbitral tribunal (the Tribunal) in its arbitration proceedings with Janssen Pharmaceutica N.V. (Janssen), a subsidiary of... Read More

Dr. Loew to Assume New Leadership Role Upon Completion of the Planned Separation of Alkermes' Oncology Business Planned Separation Remains on Track to be Completed in Second Half of 2023 DUBLIN , June 1, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that Caroline J. Loew , Ph.D., has been appointed as the chief executive officer designate of Mural Oncology plc (Mural Oncology), the new independent public... Read More

DUBLIN , May 31, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chats at two upcoming investor conferences. Jefferies Healthcare Conference Date/Time: Wednesday, June 7, 2023 at 10:00 a.m. EDT ( 3:00 p.m. BST ) Goldman Sachs 44 th Annual Global Healthcare Conference Date/Time: Monday, June 12, 2023 at 9:20 a.m. PDT ( 12:20 p.m. EDT / 5:20 p.m. BST ) The live... Read More

Company Has Outperformed Peers and Relevant Indices Since Unveiling its December 2020 Value Enhancement Plan 70% of Board's Independent Directors Have Been Appointed Over the Last Four Years, Including Four Directors Designated or Supported by Shareholders Company Launches www.AlkermesValue.com , Providing Additional... Read More

Clinical and Patient Experience Research Delivers Insights into Treatment for People Living with Schizophrenia or Bipolar I Disorder DUBLIN , May 16, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry portfolio—which includes LYBALVI ® (olanzapine and samidorphan) and ARISTADA ® (aripiprazole lauroxil)—at four scientific conferences this spring. Several of... Read More

Trial-in-Progress Posters From ARTISTRY-6 and ARTISTRY-7 Clinical Trials to be Presented DUBLIN , May 9, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the acceptance of two abstracts related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting,... Read More

DUBLIN , May 8, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today filed its preliminary proxy statement with the U.S. Securities and Exchange Commission (SEC) in connection with its upcoming Annual General Meeting of Shareholders (the Annual Meeting). The company also provided an update on its annual director nomination process and its ongoing shareholder engagement efforts. The preliminary proxy statement is available... Read More

First Quarter Revenues of $287.6 Million Reflect Strong Performance of Proprietary Product Portfolio GAAP Loss per Share of $0.25 and Basic and Diluted Non-GAAP Earnings per Share of $0.01 Planned Separation of Oncology Business Expected to be Completed in Second Half of 2023 Second Favorable Interim Award Received in Janssen Arbitration Financial Expectations for 2023 Reiterated DUBLIN , April 26, 2023 /PRNewswire/ --... Read More

DUBLIN , April 25, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that on April 19, 2023 it received a second interim award (the "Second Interim Award") from the arbitral tribunal (the "Tribunal") in its arbitration proceedings in respect of two license agreements with Janssen Pharmaceutica N.V. ("Janssen"), a subsidiary of Johnson & Johnson. Pursuant to the Second Interim Award: Back royalties related to... Read More

DUBLIN , April 19, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, April 26, 2023 to discuss the company's first quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com . The conference call may be accessed by dialing +1 877 407... Read More

Application Period to Begin on May 1, 2023 DUBLIN , April 19, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the company will accept applications for its Alkermes Inspiration Grants ® program beginning on May 1, 2023 . Now in its seventh year, this competitive grant program will provide up to a total of $500,000 in grants to assist nonprofit organizations in their work to address the needs of people... Read More

DUBLIN , April 18, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has submitted a confidential draft Form 10 registration statement to the United States Securities and Exchange Commission in connection with the previously announced planned separation of the company's oncology business into an independent, publicly-traded company (Oncology Co.). The company continues to expect to complete the... Read More

DUBLIN , March 23, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the publication of results from its phase 3 ENLIGHTEN-Early study of LYBALVI ® (olanzapine and samidorphan) in the peer-reviewed publication, the Journal of Clinical Psychiatry . ENLIGHTEN-Early evaluated the effect of LYBALVI compared to olanzapine on body weight in young adult patients (ages 16 to 39; mean age: 26 years) with schizophrenia,... Read More

DUBLIN , March 15, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat as part of the Stifel 2023 CNS Days on Wednesday, March 29, 2023 at 9:00 a.m. ET ( 2:00 p.m. BST ). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc is a fully-integrated, global biopharmaceutical... Read More

Revenues of $1.11 Billion in 2022, GAAP Loss per Share of $0.97 and Diluted Non-GAAP Earnings per Share of $0.34 Achieved LYBALVI ® Net Sales of $96.0 Million in First Full Year of Commercial Launch Accelerated Long-Term Profitability Targets Reflect Enhanced Profitability Driven by Planned Separation of Oncology Business DUBLIN , Feb. 16, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for... Read More

DUBLIN , Feb. 9, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. GMT ) on Thursday, Feb. 16, 2023 to discuss the company's fourth quarter and year-end 2022 financial results. Management will also discuss financial expectations for 2023 and provide an update on the company. The webcast player and accompanying slides may be accessed on the... Read More

Designation Marks Entry Point into MHRA's Innovative Licensing and Access Pathway (ILAP) Program in the UK DUBLIN , Jan. 17, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that nemvaleukin alfa (nemvaleukin), the company's investigational, novel engineered interleukin-2 (IL-2) variant immunotherapy, has been granted an Innovation Passport for the treatment of mucosal melanoma under the Innovative Licensing... Read More

DUBLIN , Dec. 28, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops , will provide a corporate overview and update at the 41 st Annual J.P. Morgan Healthcare Conference. The presentation will take place on Wednesday, Jan. 11, 2023 at 11:15 a.m. PST ( 2:15 p.m. EST / 7:15 p.m. GMT ), followed by a question and answer session. The live webcast may be accessed under... Read More

DUBLIN , Nov. 30, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat as part of the BofA Securities 2022 Biotech SMID Cap Conference on Wednesday, Dec. 7, 2022 at 8:00 a.m. ET ( 1:00 p.m. GMT ). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc is a fully-integrated,... Read More

DUBLIN , Nov. 22, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Tuesday, Nov. 29, 2022 at 2:40 p.m. ET ( 7:40 p.m. GMT ). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc is a fully-integrated, global... Read More